此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

AI-Guided Bronchoscopy Using the Broncho AI Navigator

2026年11月12日 更新者:Ambu A/S

Real-Time AI-Guided Bronchoscopy: A Two-Phase Clinical Study Evaluating Usability and Impact on Procedural Performance Metrics of the Broncho AI Navigator

This clinical investigation evaluates the Ambu Broncho AI Navigator, an investigational software system designed to provide real-time navigational support during bronchoscopy. The system uses artificial intelligence to identify and display airway anatomy during procedures and to help bronchoscopists track which airway segments have been examined.

The study is conducted at Odense University Hospital and consists of two phases. In Phase 2a, experienced bronchoscopists use the system during routine bronchoscopies to evaluate and optimize technical settings and usability. For this phase 45 patients will be enrolled. In Phase 2b, bronchoscopies are randomized (1:1) to be performed with or without the Broncho AI Navigator to evaluate the impact of AI guidance on procedural performance. For this phase 108 patients will be enrolled.

Adult patients undergoing elective bronchoscopy are enrolled, while the primary study subjects are the bronchoscopists performing the procedures. The study evaluates whether use of the Broncho AI Navigator improves bronchoscopy performance by increasing diagnostic completeness, improving structured progression through the bronchial tree, and reducing procedure time. The findings will support further development and future validation of the Broncho AI Navigator in clinical practice.

研究概览

地位

招聘中

研究类型

介入性

注册 (估计的)

153

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Region Syddanmark
      • Odense、Region Syddanmark、丹麦、5000
        • 招聘中
        • Odense University Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Phase 2a (System calibration):

Inclusion Criteria:

  • Patients indicated for bronchoscopy of central airways as per standard of care.
  • Patients with an age of 18 years or above.

Exclusion Criteria:

  • Patients who are unable to cooperate for bronchoscopy (e.g., patients with mental disorders, cognitive impairment, psychological disorder).
  • Patients who are unable or unwilling to give informed consent.
  • Patients with highly abnormal lung anatomy.
  • Patients with conditions which significantly impact the visual appearance of the airway tissue, such as heavy bleeding, secretions, or inflammation.
  • Patients who are pregnant or breastfeeding
  • Patients previously enrolled in either phase 2a

Phase 2b (Randomized study):

Inclusion Criteria:

  • Patients indicated for bronchoscopy of central airways as per standard of care.
  • Patients with an age of 18 years or above.

Exclusion Criteria:

  • Patients who are unable to cooperate for bronchoscopy (e.g., patients with mental disorders, cognitive impairment, psychological disorder).
  • Patients who are unable or unwilling to give informed consent.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Broncho AI Navigator

The Broncho AI Navigator is an investigational software device designed to provide real-time navigational support during bronchoscopy. The system analyzes live bronchoscopy video using artificial intelligence to identify anatomical landmarks and bronchial segments and displays this information on a monitor to assist navigation through the tracheobronchial tree. The software is evaluated as an adjunct to standard bronchoscopy procedures.

无干预:Standard Bronchoscopy

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Diagnostic completeness
大体时间:At the time of the procedure

Diagnostic completeness is defined as the bronchoscopist's ability to visualize all available tertiary bronchial segments (RB1, RB2, RB3, RB4, RB5, RB6, RB7, RB8, RB9, RB10, LB1+2, LB3, LB4, LB5, LB6, LB8, LB9, and LB10) using the bronchoscope. For the purpose of this investigation, a procedure is considered fully diagnostically complete (score of 1) if all tertiary segments are visualized. If any segments are not visualized, the procedure is deemed diagnostically incomplete (score of 0).

At the time of the procedure
Structured progression
大体时间:At the time of the procedure

The structured progression outcome is scored between 0 and 18, with 18 indicating 18 correct progressions. A point is awarded when the bronchoscopist visualizes one segment and then immediately proceeds to the succeeding segment (e.g., visualizing RB1 followed by RB2 results in a point, whereas RB2 followed by RB1 does not).

At the time of the procedure
Procedure time
大体时间:At the time of the procedure

Procedure time is defined as the duration required for the bronchoscopist to visualize all 18 segments, starting from the visualization of the first segment to the last.

At the time of the procedure

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年9月14日

初级完成 (估计的)

2027年5月30日

研究完成 (估计的)

2028年5月30日

研究注册日期

首次提交

2026年11月12日

首先提交符合 QC 标准的

2026年11月12日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • CIS-030
  • 16-0300-55 (其他标识符:Medical Research Ethics Committees (MREC), Denmark)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data (IPD) will not be made publicly available. The study includes clinical procedure data and video recordings collected for medical device development and evaluation. Data contain information that could increase the risk of re-identification, and sharing is restricted to protect participant privacy and confidentiality in accordance with applicable data protection requirements.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅